1981
Autoimmune disease doctor
Tireless leadership in the fight against infectious diseases →
Bonaventura Clotet,
President
Bonaventura Clotet, born in Barcelona in 1953, holds a PhD in Medicine from the Autonomous University of Barcelona. He is President of the Fundació Lluita contra les Infeccions, Director of the AIDS Research Institute (IrsiCaixa) and territorial director on Infectious Diseases in the management of the Northern Metropolitan Area of the Catalan Institute of Health (ICS).
In 1981, during his residency as a specialist in Internal Medicine at the Vall d’Hebron University Hospital in Barcelona, he happened to be there for the first case of AIDS in Spain. This event left its mark on him professionally and led him to lead the HIV Unit of the Germans Trias i Pujol University Hospital in Badalona. He is currently in charge of a team of more than 200 people who fight every day to do more for infectious diseases.
Autoimmune disease doctor
Head of the HIV Unit at Germans Trias Hospital
Creates and chairs the Fight Against Infections Foundation
Director of the IrsiCaixa Research Institute
National Research Award of Catalonia
Territorial Clinical Director of Infectious Diseases/MetroNord Management/ICS
Receives the Trifermed Award 2023 for social impact in health.
Dr. Bonaventura Clotet served for ten years as a member of the IAS‑USA Drug Resistance Mutations Group and was also part of the Governing Council of the International AIDS Society (IAS). His outstanding career in HIV research earned him, in 2010, the Scientific Career Award from the Catalan Institute of Health (ICS).
In 2013, Dr. Clotet received the Professional Excellence Award from the Official College of Physicians of Barcelona (COMB). Later, in 2021, he was honoured with the National Research Award of Catalonia, one of the most prestigious scientific recognitions in the country.
He is currently a scientific advisor to AELIX Therapeutics (2015) for the development of a therapeutic vaccine against HIV, to AlbaJuna Therapeutics (2016) for the development of an immunoglobulin to cure and prevent HIV, and to the DooleHealth (2015) telemedicine platform that strengthens the relationship between patients and health professionals.